HC Wainwright & Co. Reiterates Buy on Compass Therapeutics, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Compass Therapeutics (NASDAQ:CMPX) and maintained a $10 price target.
August 12, 2024 | 6:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Compass Therapeutics and maintained a $10 price target.
The reiteration of a Buy rating and maintenance of a $10 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100